Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis

References

• Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management. In: American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting 2013.
   Google Scholar
• Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–1461.
   PubMed Web of Science ®Google Scholar
• Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113:2704–2713.
   PubMed Web of Science ®Google Scholar
• Mortensen HR, Overgaard J, Specht L, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncology: Journal Eur Soc Ther Radiol Oncol. 2012;103:69–75.
   PubMed Web of Science ®Google Scholar
• Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy–European Blood and Marrow Transplantation Mucositis Advisory Group. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2008;26:1519–1525.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52:61–77, viii.
   PubMedGoogle Scholar
• Villa A, Sonis ST. Pharmacotherapy for the management of cancer regimen-related oral mucositis. Expert Opin Pharmacother. 2016;17:1801–1807.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Schubert M, Ang KK, et al. NCCN task force report. Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008;6 Suppl 1:S1-21; quiz S2-4.
   PubMedGoogle Scholar
• Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598.
   PubMed Web of Science ®Google Scholar
• Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010;16:597–600.
   PubMed Web of Science ®Google Scholar
• Eilers J. Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. Oncol Nurs Forum. 2004;31:13–23.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 1999;85:2103–2113.
   Google Scholar
• Wygoda A, Maciejewski B, Skladowski K, et al. Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. Int J Radiat Oncol Biol Phys. 2009;73:384–390.
   PubMed Web of Science ®Google Scholar
• Schüler P, Buckley B. Re-engineering clinical trials. In: Peter Schueler and Brendan Buckleye (eds). Best practices for streamlining the development process. Elsevier. 2015.
   Google Scholar
• Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011;29:2808–2814.
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol. 2007;18:817–826.
   PubMed Web of Science ®Google Scholar
• Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21:2075–2083.
   PubMed Web of Science ®Google Scholar
• Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5:3–11.
   PubMedGoogle Scholar
• Russi EG, Raber-Durlacher JE, Sonis ST. Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. Mediators Inflamm. 2014;2014:518261.
   PubMed Web of Science ®Google Scholar
• Reyes-Gibby CC, Melkonian SC, Wang J, et al. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: an informative gene network analysis. PLoS One. 2017;12:e0180396.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Selim MA, El-Sayed NM. alpha-Lipoic acid ameliorates oral mucositis and oxidative stress induced by methotrexate in rats. Histological and immunohistochemical study. Life Sci. 2017;171:51–59.
   PubMed Web of Science ®Google Scholar
• Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016;239:115–125.
   PubMed Web of Science ®Google Scholar
• Anderson CM, Sonis ST, Lee CM, et al. Phase 1b/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2017. pii: S0360-3016(17)34024-5.
   Web of Science ®Google Scholar
• Sonis S, Haddad R, Posner M, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007;43:289–300.
   PubMed Web of Science ®Google Scholar
• Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13:380–389.
   PubMedGoogle Scholar
• Logan RM, Gibson RJ, Sonis ST, et al. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncology. 2007;43:395–401.
   PubMed Web of Science ®Google Scholar
• Chang CT, Ho TY, Lin H, et al. 5-Fluorouracil induced intestinal mucositis via nuclear factor-kappaB activation by transcriptomic analysis and in vivo bioluminescence imaging. PLoS One. 2012;7:e31808.
   PubMed Web of Science ®Google Scholar
• Han G, Bian L, Li F, et al. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med. 2013;19:421–428.
   PubMed Web of Science ®Google Scholar
• Logan RM, Gibson RJ, Bowen JM, et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62:33–41.
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews. 2007;33:448–460.
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, et al. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther. 2008;7:1139–1145.
   PubMed Web of Science ®Google Scholar
• Bertolini M, Sobue T, Thompson A, et al. Chemotherapy induces oral mucositis in mice without additional noxious stimuli. Transl Oncol. 2017;10:612–620.
   PubMed Web of Science ®Google Scholar
• Beutheu Youmba S, Belmonte L, Galas L, et al. Methotrexate modulates tight junctions through NF-kappaB, MEK, and JNK pathways. J Pediatr Gastroenterol Nutr. 2012;54:463–470.
   PubMed Web of Science ®Google Scholar
• Yahyapour R, Amini P, Rezapoor S, et al. Targeting of inflammation for radiation protection and mitigation. Curr Mol Pharmacol. 2017. doi: 10.2174/1874467210666171108165641. [Epub ahead of print].
   PubMedGoogle Scholar
• Ribeiro SB, De Araujo AA, Araujo Junior RF, et al. Protective effect of dexamethasone on 5-FU-induced oral mucositis in hamsters. PLoS One. 2017;12:e0186511.
   PubMed Web of Science ®Google Scholar
• Hwang D, Popat R, Bragdon C, et al. Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:321–329.
   PubMed Web of Science ®Google Scholar
• Al-Azri AR, Gibson RJ, Bowen JM, et al. Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. J Oral Pathol Med. 2015;44:459–467.
   PubMed Web of Science ®Google Scholar
• Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–284.
   PubMed Web of Science ®Google Scholar
• Vasconcelos RM, Sanfilippo N, Paster BJ, et al. Host-microbiome cross-talk in oral mucositis. J Dent Res. 2016.
   PubMed Web of Science ®Google Scholar
• Mensa B, Howell GL, Scott R, et al. Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014;58:5136–5145.
   PubMed Web of Science ®Google Scholar
• Scott RW, Tew GN. Mimics of host defense proteins; strategies for translation to therapeutic applications. Curr Top Med Chem. 2017;17:576–589.
   PubMed Web of Science ®Google Scholar
• Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnol Rep (Amst). 2017;15:24–26.
   PubMedGoogle Scholar
• Limaye SA, Haddad RI, Cilli F, et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013;119:4268–4276.
   PubMed Web of Science ®Google Scholar
• Attali P, Zakin L, Nicole B, et al. Effect of clonidine on proinflammatory cytokine levels in ex vivo human oral mucosa. J Clin Oncol. 2014;32.
   Web of Science ®Google Scholar
• Giralt J, Tao YR, Bensadoun RJ, et al. Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in head and neck cancer patients: a phase II randomized trial. J Clin Oncol. 2015;33:6058-6058.
   PubMedGoogle Scholar
• Yokota T, Ogawa T, Takahashi S, et al. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer. 2017;17:314.
   PubMed Web of Science ®Google Scholar
• Yokota T, Hamauchi S, Yoshida Y, et al. The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients. Annals of Oncology. 2017;28:v372–v94.
   Web of Science ®Google Scholar
• Lee B, Bohmann J, Reeves T, et al. alpha- and beta-santalols directly interact with tubulin and cause mitotic arrest and cytotoxicity in oral cancer cells. J Nat Prod. 2015;78:1357–1362.
   PubMed Web of Science ®Google Scholar
• Sharma M, Levenson C, Bell RH, et al. Suppression of lipopolysaccharide-stimulated cytokine/chemokine production in skin cells by sandalwood oils and purified alpha-santalol and beta-santalol. Phytother Res. 2014;28:925–932.
   PubMed Web of Science ®Google Scholar
• Rao S, Hegde SK, Baliga-Rao MP, et al. Sandalwood oil and turmeric-based cream prevents ionizing radiation-induced dermatitis in breast cancer patients: clinical study. Medicines (Basel). 2017;4(3). pii: E43. doi: 10.3390/medicines4030043.
   Google Scholar
• Jones JW, Jackson IL, Vujaskovic Z, et al. Targeted metabolomics identifies pharmacodynamic biomarkers for BIO 300 mitigation of radiation-induced lung injury. Pharm Res. 2017.
   Web of Science ®Google Scholar
• Jackson IL, Zodda A, Gurung G, et al. BIO 300, a nanosuspension of genistein, mitigates pneumonitis/fibrosis following high-dose radiation exposure in the C57L/J murine model. Br J Pharmacol. 2017;174(24):4738-4750. doi: 10.1111/bph.14056. Epub 2017 Nov 3.
   Web of Science ®Google Scholar
• Kim JW, Kim MG, Lee HJ, et al. Topical recombinant human epidermal growth factor for oral mucositis induced by intensive chemotherapy with hematopoietic stem cell transplantation: final analysis of a randomized, double-blind, placebo-controlled, phase 2 trial. PLoS One. 2017;12:e0168854.
   PubMed Web of Science ®Google Scholar
• Framroze B. Potential of ST-617 to prevent the occurrence and reduce the duration of severe oral mucositis. In: MASCC/ISOO 2016 annual meeting webcasts. 2016. Available from: http://www.mascc.org/webcasts-2016
   Google Scholar
• Chen P, Lingen M, Sonis ST, et al. Role of AMP-18 in oral mucositis. Oral Oncol. 2011;47:831–839.
   PubMed Web of Science ®Google Scholar
• Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol. 2015;27:159–164.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Sonis ST. Genomics, personalized medicine, and supportive cancer care. Am Soc Clin Oncol Educ Book. 2015;9–16.
   PubMedGoogle Scholar